首页/数据集/Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations

Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations

NIAID Data Ecosystem2026-03-06 收录

转移性结直肠癌三线治疗

KRAS野生型靶向治疗

数据链接：

https://www.omicsdi.org/dataset/ecrin-mdr-crc/2064058 数据链接链接失效反馈

官方服务：

资源简介：

The purpose of this study is to investigate the effect and the side effect profile of irinotecan and panitumumab administered every 3 weeks as 3rd line treatment for patients with metastatic colorectal cancer without KRAS mutations.

应用场景：

创建时间：

2008-11-15

结直肠癌肝转移治疗

KRAS野生型靶向治疗

Interventions: Surgical hepatectomy followed by chemotherapy (mFOLFOX6) 12cycles. mFOLFOX6(L-OHP 85 mg/m2/biweekly, Levofolinate 200 mg/m2/biweekly, 5-FU/bolus 400 mg/m2/biweekly, 5-FU/continuous 2,40

NIAID Data Ecosystem80

Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study)

结直肠癌靶向治疗

KRAS野生型靶向治疗

This is an open-label, non-randomized, multicenter Phase II study evaluating folinic acid + fluorouracil + irinotecan (FOLFIRI) plus cetuximab (Erbitux) or folinic acid + fluorouracil + oxaliplatin (F

NIAID Data Ecosystem50

Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

结直肠癌靶向治疗

KRAS野生型靶向治疗

This study is a global, multicenter, open-label phase 1b and randomized, double-blinded, 2 part, phase 2 study designed to evaluate the safety and efficacy of rilotumumab or ganitumab in combination w

NIAID Data Ecosystem40

Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients

结直肠癌肝转移术后治疗

KRAS野生型靶向治疗

Up to 50% of patients with colorectal cancer (CRC) develop liver metastasis during the course of their disease. In 30-40% of patients metastasis is confined to the liver. In these patients R0-resectio

NIAID Data Ecosystem50

Phase II study of first-line WHIT panitumumab and capecitabine in elderly patients with metastatic colorectal cancer and wild type KRAS

转移性结直肠癌治疗

KRAS野生型靶向治疗

Primary objectives: Evaluar la tasa de respuesta en sujetos ancianos tratados con panitumumab y capecitabina como régimen de quimioterapia de primera línea en sujetos con CCRm KRAS no mutado. Primary

NIAID Data Ecosystem40

Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations

资源简介：

相关数据集